Nasdaq atai.

NEW YORK, Nov. 29, 2021-- atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it has increased its ...Topline results are expected in the first half of 2024. NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage ...NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental ...4 days ago ... Atai Life Sciences N.V.'s stock symbol is ATAI and currently trades under NASDAQ. It's current price per share is approximately $1.12. How much ...

Atai Life Sciences N.V. (NASDAQ:ATAI) (announced setting up of a subsidiary for studying Salvinorin A for mental health disorders) Axsome Therapeutics, Inc. (NASDAQ:AXSM) Aytu Biopharma, Inc ...With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (ATAI-1.75%) is having a rough go of things lately ...

Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...He was also CFO of atai Life Sciences (Nasdaq: ATAI), completing over $282M in late-stage private financings and led a successful $258M IPO at a $2.3B valuation to support the acquisition of ...

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101. - This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics ...ATAI Life Sciences (NASDAQ: ATAI) is another clinical-stage biotech looking to make a mark in the mental health space. Its stock took a dive recently following failed results of its Phase 2a study ...As of August 2, 2023, the average one-year price target for ATAI Life Sciences N.V. is 12.51. The forecasts range from a low of 5.15 to a high of $22.05. The average price target represents an ...Clinical-stage biotech DemeRx, which is part of Atai Life Sciences’ (NASDAQ:ATAI) portfolio, has completed phase 1 trials for noribogaine and is now planning to launch a phase 2 trial on a ...

Nov 29, 2023 · The average trading volume of ATAI on November 29, 2023 was 536.92K shares. ATAI) stock’s latest price update. The stock price of ATAI Life Sciences N.V. (NASDAQ: ATAI) has plunged by -3.51 when compared to previous closing price of 1.14, but the company has seen a 2.80% gain in its stock price over the last five trading sessions.

NEW YORK and BERLIN, Dec. 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical stage biopharmaceutical company aiming to transform the ...

ATAI ATAI Life Sciences. Close 12/01 16:00 ET. 1.120. +0.080 +7.69%. High 1.150 ... (NASDAQ:ATAI) shares closed up 4.67% at $1.12Mind Medi. Benzinga11-23 04:30 ET.Based on 2 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $20.00 with a high ...NEW YORK and BERLIN, Aug. 10, 2023-- atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 ...ATAI Life Sciences N.V. Common Shares (ATAI) Stock Price, Quote, News & History | Nasdaq MY QUOTES: ATAI Edit my quotes ATAI Life Sciences N.V. Common Shares (ATAI) 0 Add to Watchlist...Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).

Mar 31, 2023 · Shares of Atai Life Sciences ( ATAI 7.69%), a clinical-stage biopharmaceutical company that is developing therapies from psychedelics to treat mental health conditions, saw its shares rise 12.41% ... Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.Atai Life Sciences (NASDAQ:ATAI) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the superior business?We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings.The average one-year price target for ATAI Life Sciences N.V. (NASDAQ:ATAI) has been revised to 12.57 / share. This is an increase of 5.04% from the prior estimate of 11.97 dated August 31, 2023. Atai Life Sciences N.V. (NASDAQ:ATAI) is a promising clinical-stage biopharmaceutical company that creates and funds businesses focusing on developing psychedelic-based treatments.While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to ...

NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy – the medically …

Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...Atai Life Sciences Nv 's revenue in 2023 is $334,000.On average, 2 Wall Street analysts forecast ATAI's revenue for 2023 to be $124,507,857, with the lowest ATAI revenue forecast at $49,803,143, and the highest ATAI revenue forecast at $199,212,571.The latest price target for ATAI Life Sciences ( NASDAQ: ATAI) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 20.00 expecting ATAI to rise ...As of March 2015, Theranos is a private company and does not have a public stock symbol. The medical technology company has a partnership with the public company, Walgreens, which has a stock symbol of WAG on Nasdaq.atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been ...- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023. - VLS-01 is a synthetic form of N,N-dimethyltryptamine ...

atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ...

NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for ...

Atai Life Sciences (NASDAQ:ATAI) closed at $1.06, down from prior weeks’ closings at $1.3, $1.28, $1.39 and $1.29. Incannex Healthcare (NASDAQ:IXHL) closed at $0.99, up from prior week’s close ...On December 2, 2023, the Board appointed Sahil Kirpekar, M.D. and Ryan Barrett as the new atai Board designees pursuant to the Rights Agreement, to serve until …Nov 17, 2023 ... atai Life Sciences N.V. (ATAI) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy).Atai Life Sciences N.V. (NASDAQ:ATAI) was down, falling 38% to $1.63 after the company announced Perception Neuroscience's Phase 2a clinical trial did not meet its primary endpoint.Atai Life Sciences (NASDAQ:ATAI) closed at $1.29, almost the same as Friday 22’s closing price $1.30 and also down from past weeks’ closings ($1.45 and $1.43.)On September 13, 2023, Florian Brand, See Remarks at ATAI Life Sciences NV (NASDAQ:ATAI), made a significant purchase of 40,000 shares of the company's stock. Benzinga.8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...ATAI NASDAQ. ATAI NASDAQ. ATAI NASDAQ. Market closed Market closed. No trades. See on Supercharts. Overview News Ideas Financials Technicals . Forecast . Price target. 13.80 0.00 0.00%. The 5 analysts offering 1 year price forecasts for ATAI have a max estimate of — and a min estimate of —.Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ...NEW YORK, Dec. 13, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ('atai' or the 'Company'), a global biotech company developing psychedelic and non-psyc... NEW YORK, Dec. 16, 2020 /PRNewswire/ -- atai Life Sciences ("atai" or the "Company"), a gl...ATAI Life Sciences N.V. Common Shares (ATAI) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

atai Life Sciences atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet ...Dec 23, 2022 · NEW YORK and BERLIN, Dec. 23, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical stage biopharmaceutical company aiming to transform the ... Aug 15, 2022 ... atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ...NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more.Instagram:https://instagram. is it good time to invest in real estatediamond etfspyd dividend yieldlockheed martin corp stock 3. Psychedelics Stocks Rise In First Post-Tax Loss Selling Week. The psychedelic sector rose moderately in the first week of 2023 past week, as reflected by the Horizon Psychedelic Stock Index (PSYK) ETF ↑4.70%.Despite a negative readout for atai Life Sciences compound PCN-101, the market ended higher and sharply outperformed …Find the latest SEC Filings data for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com. boat dock insurancestock tlt Find the latest analyst research for ATAI Life Sciences N.V. Common Shares (ATAI) at Nasdaq.com.Atai Life Sciences N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023. CI. Nov. 14. Atai Life Sciences N.V. acquired … vmrxx interest rate 31dfe48811d2.q4INGxiFDVnmwbNEPLSmjL3zAvKTd4nY4VaO5TL8Qr4.wrRFckjAe2GI7PA3U4fK …Ticker Symbol: ATAI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $15.00: CIK Code: 0001840904: CUSIP Number: N0731H103 ...